Product Information
GS DUAL ACTION PAIN 250-125 MG is a generic product labeled by L. Perrigo Company, priced at $0.1071 per EA under NDC 00113530016. Its NADAC has been published 133 times since Mar 20, 2024.
FDA first approved this application on Feb 28, 2023.
Strength
250; 125 mg/1; mg/1
Manufacturer
L. Perrigo CompanyNDC
00113530016
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA214836FDA Approved
2/28/2023
On Market Since
3/1/2023
Pharmacological Classes
Price Statistics
The NADAC for GS DUAL ACTION PAIN 250-125 MG has been published 133 times since Mar 20, 2024, and over the history we have for it it has risen 69.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1071 per EA |
|---|---|
| All-time high | $0.1086 (Jul 16, 2025) |
| All-time low | $0.0610 (May 22, 2024) |
| 52-week high | $0.1071 |
| 52-week low | $0.0839 |
| Median price | $0.0894 |
| Average price | $0.0872 |
| Largest weekly change | +15.2% (Jul 17, 2024) |
| Weeks tracked | 133 |
| Tracking since | Mar 20, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen, Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS DUAL ACTION PAIN 250-125 MG?
The current National Average Drug Acquisition Cost (NADAC) for GS DUAL ACTION PAIN 250-125 MG, manufactured by L. Perrigo Company, is $0.1071 per EA (NDC 00113530016), effective Sep 30, 2026.
How has the price of GS DUAL ACTION PAIN 250-125 MG changed over time?
Over the history we have for it, the NADAC for GS DUAL ACTION PAIN 250-125 MG has risen 69.9%. It has been tracked across 133 weekly CMS publications since Mar 20, 2024.
What are the highest and lowest recorded NADAC prices for GS DUAL ACTION PAIN 250-125 MG?
Since Mar 20, 2024, the NADAC for GS DUAL ACTION PAIN 250-125 MG has ranged from a low of $0.0610 (May 22, 2024) to a high of $0.1086 (Jul 16, 2025), with a median of $0.0894 per EA.
Are there cheaper alternatives to GS DUAL ACTION PAIN 250-125 MG?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GS DUAL ACTION PAIN 250-125 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures GS DUAL ACTION PAIN 250-125 MG?
GS DUAL ACTION PAIN 250-125 MG (NDC 00113530016) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.